The content discusses the importance of biomarkers in managing Crohn's disease, highlighting the recent clinical practice guideline by the American Gastroenterological Association (AGA). The guideline emphasizes the significance of serum and fecal biomarkers in tracking treatment response, offering key recommendations for their application. The evolving role of biomarkers in CD management is explored, focusing on their ability to assess inflammation status and guide treatment decisions. The content delves into specific insights provided by the guidelines, such as the reliability of biomarkers in different scenarios and their potential to replace endoscopy in certain cases. Additionally, the AGA panel's 11 recommendations are outlined, addressing the use of biomarkers in symptomatic remission, active CD, and surgically induced remission. The impact of these recommendations on clinical practice and future developments in biomarker utilization are also discussed.
翻譯成其他語言
從原文內容
www.medscape.com
從以下內容提煉的關鍵洞見
by Kate O'Rourk... 於 www.medscape.com 01-23-2024
https://www.medscape.com/viewarticle/aga-guideline-makes-case-biomarkers-have-clear-role-managing-2024a10001ps深入探究